Cargando…
Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
A granule formulation of baloxavir marboxil, a selective inhibitor of influenza cap-dependent endonuclease, was newly developed for children with difficulty swallowing tablets. METHODS: A multicenter open-label study was conducted during the 2017–2018 influenza season to assess the safety, pharmacok...
Autores principales: | Yokoyama, Takato, Sakaguchi, Hiroki, Ishibashi, Toru, Shishido, Takao, Piedra, Pedro A., Sato, Chisako, Tsuchiya, Kenji, Uehara, Takeki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360099/ https://www.ncbi.nlm.nih.gov/pubmed/32433222 http://dx.doi.org/10.1097/INF.0000000000002748 |
Ejemplares similares
-
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020) -
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018) -
LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018) -
Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
por: Baker, Jeffrey, et al.
Publicado: (2020) -
Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study
por: Baker, Jeffery B., et al.
Publicado: (2023)